Drug intelligence / Profile preview

TBIO002

Development stage: Unknown
Lead developer: Tailor Biosciences
Modality: Small Molecules

Overview

TBIO002 is a small molecule therapeutic being developed by Tailor Biosciences for the treatment of solid tumors. It operates through a synthetic lethal mechanism targeting an oncogenic-signaling pathway. The drug is designed to be used in conjunction with a companion diagnostic (TBIO002 CDx) that identifies chromosomal instability (CIN) biomarkers, allowing for a precision medicine approach to patient selection. As of 2024, the program is in Phase 1 development, with the company actively fundraising to in-license the asset.

Beyond the preview

Go deeper on TBIO002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBIO002.

Explore the full profile